*仅供医学专业人士阅读参考 T2DM治疗之求索 创新制剂,合二为一 T2DM治疗之证据 从“理想研究”到“真实世界” T2DM治疗之应用 在中国人群中的实践探索 小结 参考文献: [1] 中华医学会糖尿病学分会. 中华糖尿病杂志. 2021; 13(4): 315-409. [2] Janardhan S, Sastry GN. Curr Drug Targets. 2014 Jun;15(6):600-21. [3] Haipeng Wang, et al. BMJ Open. 2020 Apr 6;10(4):e036331. [4]Cantini G, et al. Trends Endocrinol Metab. 2016 Jun;27(6):427-438. [5]冉兴无. 等. 中国糖尿病杂志. 2020;28(10):721-728. [6] Qi Dai , et al. BMC Endocr Disord. 2021 May 22;21(1):104. [7] Cernea S, Raz I. Diabetes Care. 2011 May;34 Suppl 2(Suppl 2):S264-71. [8] Grigoropoulou P, et al. Curr Diabetes Rev. 2013;9(5):412-7.Shao Y, et al. [9]Luo X, et al. J Diabetes. 2013 Dec; 5(4):421-428. [10]Cantini G, et al. Trends Endocrinol Metab. 2016 Jun;27(6):427-438. [11]Grigoropoulou P, et al. Curr Diabetes Rev. 2013;9(5):412-7. [12]Buse JB, et al. Diabetes Care. 2014;37(11):2926-33. [13]Linjawi S, et al. Diabetes Ther. 2017;8(1):101-114. [14]Rodbard HW, et al. Diabet Med. 2017;34(2):189-196. [15]Lingvay I, et al. JAMA. 2016;315(9):898-907. [16]Harris SB, et al. Diabetes Obes Metab. 2017;19(6):858-865. [17]Billings LK, et al. Diabetes Care. 2018;41(5):1009-1016. [18]Aroda VR, et al. Lancet Diabetes Endocrinol. 2019;7(8):596-605. [19]Philis-Tsimikas A, et al. Diabetes Obes Metab. 2019;21(6):1399-1408. [20]Gough SC, et al. Diabetes Obes Metab. 2015;17(10):965-73. [21] Price H, et al. Diabetes Obes Metab. 2018 Apr;20(4):954-962. [22] Weiqing W, et al. 2020 EASD. ePoster presentation 689. [23] Novo Nordisk. NN9068-4166. Data on file. [24] Pei Y,et al.Diabetes Obes Metab. 2021 Aug 13. “此文仅用于向医疗卫生专业人士提供科学信息,不代表平台立场” |
|